

# Alkyl Amines

## The good gets better

Our BUY recommendation on AACL with a TP of INR 2,500 is premised on (1) Robust demand from pharmaceutical and agrochemical industry that form 70% of revenue mix, (2) Rising market share in Methyl Amines, and (3) Impending capacity expansion for multiple products, including the high-margin Acetonitrile.

- **View on the result:** EBITDA/APAT were 53/86% above expectations, largely owing to (1) 4% lower raw material cost (2) Higher EBITDA margins than anticipated (28.8% vs. est. 20.3%), particularly led by Acetonitrile.
- **Value and volume led growth:** For FY20, sales jumped 17% to INR 10bn, led by 18%+ increase in volume. Tight supply of Acetonitrile in the global market bumped up EBITDA to INR 2,590mn (+59% YoY) and margins to 26.1% (19.3% in FY19). We expect the current elevated prices of Acetonitrile to sustain in the near term.
- **Gross margins improve:** Backed by Acetonitrile, AACL reported its highest ever gross margins of 51.2% for FY20 which is ~500 bps above its long term average gross margin. GM in 4Q jumped to 54.0% vs. 40.3% YoY. We expect GM to correct to 51.1/49.5% in FY21/22 in tandem with increase in RMC with increase in crude oil prices (methanol, and ammonia prices). Similarly, EBITDAM should cool off to 24.3/25.1% as demand reduces given Covid-19 and product prices come off.
- **Impending capacity expansion:** AACL is executing projects worth INR 3bn to expand its Methyl Amines (by 15kTPA), its derivatives and Acetonitrile (by 15kTPA) capacity at their Dahej and Kurkumbh facilities.
- **Outlook on EBITDA:** We expect EBITDA to dip by 4% YoY to INR 2,476mn in FY21 (impacted by the pandemic) and jump 23% YoY thereafter to INR 3,048mn backed by (1) Capacity augmentation for Acetonitrile and ramp up in production of Methyl Amines (2) Anticipation of sustainability of the current elevated prices of Acetonitrile that will continue to push EBITDA.
- **View on the consolidated balance sheet:** AACL's cash jumped 60% YoY to INR 323mn leading to a 89% YoY dip in Net debt to INR 157mn. Net Debt/Equity and Net Debt/EBITDA reduced to zero vs. 0.4x/0.9x in FY19. RoIC improved further to 32.6% vs. 18.2/15.9/15.9% in FY19/FY18/FY17.
- **Change in estimates:** We raise our FY22 EPS estimate by 13% to INR 109.0 due to a 22% tax rate guidance by the management vs. our earlier estimated 25%, and in anticipation of (1) Faster recovery in demand, and (2) Sustainability of elevated Acetonitrile prices given global supply constraints.
- **DCF based valuation:** Our TP is INR 2,500 based on Sep-21E cash flows (WACC 10%, Terminal growth rate 3.0%). The stock is trading at 18.7x FY22 EPS.

### Standalone Financial Summary

Year Ending	4Q	3Q	QoQ	4Q	YoY	FY19	FY20P	FY21E	FY22E
March (INR mn)	FY20	FY20	(%)	FY19	(%)				
Revenues	2,348	2,569	(8.6)	2,375	(1.1)	8,464	9,929	10,185	12,128
EBITDA	676	726	(6.9)	384	76.1	1,644	2,590	2,476	3,048
APAT	492	550	(10.5)	176	180.3	837	1,798	1,740	2,225
AEPS (INR)	24.1	27.0	(10.5)	8.6	180.3	41.1	88.2	85.3	109.1
P/E (x)						49.6	23.1	23.9	18.7
EV/EBITDA (x)						26.2	16.1	16.5	13.0
RoE (%)						25.3	47.8	28.4	28.3

Source: Company, HSIE Research

## BUY

CMP (as on 25 Jun 2020)	INR 2,045
Target Price	INR 2,500
NIFTY	10,289

KEY CHANGES	OLD	NEW
Rating	BUY	BUY
Price Target	INR 2,300	INR 2,500
	FY21E	FY22E
EPS %	-1.0	+12.9

### KEY STOCK DATA

Bloomberg code	AACL IN
No. of Shares (mn)	20
MCap (INR bn) / (\$ mn)	42/552
6m avg traded value (INR mn)	86
52 Week high / low	INR 2,285/653

### STOCK PERFORMANCE (%)

	3M	6M	12M
Absolute (%)	70.7	96.3	153.9
Relative (%)	48.6	112.3	165.5

### SHAREHOLDING PATTERN (%)

	Mar-20	Dec-19
Promoters	74.19	74.19
FIs & Local MFs	1.73	1.10
FPIs	0.67	0.38
Public & Others	23.41	24.28
Pledged Shares	0.0	0.0

Source : BSE

### Nilesh Ghuge

nilesh.ghuge@hdfcsec.com  
+91-22-6171-7342

### Harshad Katkar

harshad.katkar@hdfcsec.com  
+91-22-6171-7319

### Divya Singhal

divya.singhal@hdfcsec.com  
+91-22-6171-7348

## Takeaways from the earnings conference call:

- **Sales mix:** Amines form 50% of revenue mix for AACL, Derivatives and Other Specialty Chemicals each form 25% of the mix. Geographical mix: exports 15-20%, domestic sales balance 80-85%.
- **Plant utilisation in FY20:** Overall 80-85% for 12 plants. Some plants however, operated at slightly higher utilisation, namely acetonitrile and Methyl Amines.
- **Delays in capacity augmentation projects:** Manpower shortage and delays in equipment delivery have postponed AACL's Amines derivative plant at Dahej to 2QFY21 (earlier, 1QFY21). Similarly, commencement of the Acetonitrile plant has been pushed from 4QFY21 to FY22. At peak utilisation, both plants put together are expected to contribute INR 4-5bn to the topline at current prices.
- **1QFY21:** The lockdown affected plant utilisation level through Apr and May-20. However, in June, utilisation is back to near normal levels.
- **Acetonitrile:** Domestic capacity additions are not a threat for AACL as the product has a ready export market. As there are global buyers of the product, India does not have the ability to dictate prices. Prices are expected to remain elevated as the global capacity additions are largely for Acrylonitrile, a by-product of which is Acetonitrile. However, this process produces Acetonitrile of a slightly inferior quality than what AACL produces via Acetic acid route.

### Quarterly Financial Snapshot (Standalone)

(INR mn)	4QFY20	3QFY20	QoQ (%)	4QFY19	YoY (%)	FY20	FY19	YoY (%)
Net Sales	2,348	2,569	(8.6)	2,375	(1.1)	9,929	8,464	17.3
Raw Material Expenses	1,079	1,146	(5.9)	1,417	(23.9)	4,845	4,605	5.2
Employee Expenses	170	190	(10.9)	126	34.1	696	528	31.9
Other Expenses	423	507	(16.5)	447	(5.3)	1,797	1,700	5.7
<b>EBITDA</b>	<b>676</b>	<b>726</b>	<b>(6.9)</b>	<b>384</b>	<b>76.1</b>	<b>2,590</b>	<b>1,631</b>	<b>58.8</b>
<b>EBITDA Margin (%)</b>	<b>28.8</b>	<b>28.2</b>		<b>16.2</b>		<b>26.1</b>	<b>19.3</b>	
Depreciation	72	68	5.9	65	11.4	269	233	15.3
EBIT	604	658	(8.2)	319	89.2	2,321	1,398	66.0
Other Income	26	22	20.9	16	63.1	70	52	35.7
Interest Cost	19	21	(11.3)	33	(43.0)	103	147.7	(30.6)
EO Items	-	328	NA	-	NA	308	-	NA
<b>PBT</b>	<b>611</b>	<b>986</b>	<b>(38.1)</b>	<b>302</b>	<b>102.3</b>	<b>2,597</b>	<b>1,302</b>	<b>99.5</b>
Tax	119	216	(44.8)	126	(5.9)	444	464.5	(4.4)
<b>RPAT</b>	<b>492</b>	<b>771</b>	<b>(36.2)</b>	<b>176</b>	<b>180.3</b>	<b>2,153</b>	<b>837</b>	<b>157.1</b>
EO Items (Adj For Tax)	-	221	-	-	-	354.8	-	-
<b>APAT</b>	<b>492</b>	<b>550</b>	<b>(10.5)</b>	<b>176</b>	<b>180.3</b>	<b>1,798</b>	<b>837</b>	<b>114.7</b>
AEPS	24.1	27.0	(10.5)	8.6	180.3	88.2	41.1	114.7


Source: Company, HSIE Research

### Margin Analysis (Standalone)

	4QFY20	3QFY20	QoQ (bps)	4QFY19	YoY (bps)	FY20	FY19	YoY (bps)
Raw Material Expenses % Net Sales	46.0	44.6	135	59.7	(1,372)	48.8	54.4	(561)
Employee Expenses % Net Sales	7.2	7.4	(19)	5.3	190	7.0	6.2	78
Other Expenses % Net Sales	18.0	19.7	(170)	18.8	(80)	18.1	20.1	(199)
<b>EBITDA Margin (%)</b>	<b>28.8</b>	<b>28.2</b>	<b>54</b>	<b>16.2</b>	<b>1,263</b>	<b>26.1</b>	<b>19.3</b>	<b>681</b>
Tax Rate (%)	19.5	21.9	(238)	21.2	(173)	17.1	35.7	(1,857)
<b>APAT Margin (%)</b>	<b>21.0</b>	<b>21.4</b>	<b>(45)</b>	<b>7.4</b>	<b>1,357</b>	<b>18.1</b>	<b>9.9</b>	<b>821</b>


Source: Company, HSIE Research

### Historical Gross margin trend



Source: Company, HSIE Research

### Historical EBITDA margin trend



Source: Company, HSIE Research

## Change in estimates

INR mn	FY21E			FY22E		
	Old	New	% Ch	Old	New	% Ch
Net Sales	11,150	10,185	(8.6)	12,240	12,128	(0.9)
EBIDTA	2,715	2,476	(8.8)	3,040	3,048	0.3
APAT	1,759	1,740	(1.0)	1,970	2,225	12.9
EPS (INR/sh)	86.2	85.3	(1.0)	96.6	109.1	12.9

Source: Company, HSIE Research

## Peer Set Comparison (Consolidated)

Company	Mcap (INR bn)	CMP (INR/sh)	Reco	TP	EPS (INR/sh)			P/E (x)			P/BV (x)			RoE (%)		
					FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Vinati Organics	102.37	996	SELL	825	32.5	29.5	32.1	30.7	33.7	31.0	8.0	7.2	6.3	28.6	22.4	21.6
Navin Fluorine	76.83	1,557	ADD	1,721	82.6	46.9	65.0	18.8	33.2	24.0	5.5	4.9	4.3	32.9	15.5	19.0
Galaxy Surfactants	49.95	1,409	BUY	1,889	53.6	44.0	85.9	26.3	32.1	16.4	4.8	4.3	3.5	19.9	14.1	23.5
<b>Alkyl Amines</b>	<b>41.60</b>	<b>2,045</b>	<b>BUY</b>	<b>2,500</b>	<b>88.2</b>	<b>85.3</b>	<b>109.1</b>	<b>23.1</b>	<b>23.9</b>	<b>18.7</b>	<b>7.7</b>	<b>6.0</b>	<b>4.7</b>	<b>47.8</b>	<b>28.4</b>	<b>28.3</b>
Balaji Amines	14.77	456	BUY	561	30.1	35.7	46.0	15.2	12.8	9.9	2.2	1.9	1.6	14.6	14.6	15.9

Source: Company, HSIE Research

## Financials

### Consolidated Income Statement

YE Mar (INR mn)	FY17	FY18	FY19	FY20	FY21E	FY22E
Net Revenues	5,006	6,162	8,464	9,929	10,185	12,128
<i>Growth (%)</i>	3.5	23.1	37.4	17.3	2.6	19.1
Material Expenses	2,633	3,342	4,605	4,845	4,982	6,126
Employee Expenses	372	420	528	696	766	843
Other Operating Expenses	1,050	1,235	1,688	1,797	1,962	2,112
EBITDA	951	1,164	1,644	2,590	2,476	3,048
<b>EBITDA Margin (%)</b>	<b>19.0</b>	<b>18.9</b>	<b>19.4</b>	<b>26.1</b>	<b>24.3</b>	<b>25.1</b>
EBITDA Growth (%)	4.6	22.4	41.1	57.6	(4.4)	23.1
Depreciation	143	157	233	269	311	361
<b>EBIT</b>	<b>809</b>	<b>1,008</b>	<b>1,410</b>	<b>2,321</b>	<b>2,165</b>	<b>2,686</b>
Other Income (Including EO Items)	11	32	39	379	125	221
<b>Interest</b>	<b>81</b>	<b>81</b>	<b>148</b>	<b>103</b>	<b>58</b>	<b>55</b>
PBT	739	958	1,302	2,597	2,231	2,852
Tax	236	315	465	444	491	627
<b>RPAT</b>	<b>504</b>	<b>643</b>	<b>837</b>	<b>2,153</b>	<b>1,740</b>	<b>2,225</b>
<b>EO (Loss) / Profit (Net Of Tax)</b>				<b>355</b>		
<b>APAT</b>	<b>504</b>	<b>643</b>	<b>837</b>	<b>1,798</b>	<b>1,740</b>	<b>2,225</b>
<b>APAT Growth (%)</b>	<b>1.0</b>	<b>27.7</b>	<b>30.3</b>	<b>157.1</b>	<b>(19.2)</b>	<b>27.8</b>
<b>AEPS</b>	<b>24.7</b>	<b>31.5</b>	<b>41.1</b>	<b>88.2</b>	<b>85.3</b>	<b>109.1</b>
<b>AEPS Growth (%)</b>	<b>1.0</b>	<b>27.7</b>	<b>30.4</b>	<b>114.7</b>	<b>(3.2)</b>	<b>27.8</b>

Source: Company, HSIE Research

### Consolidated Balance Sheet

YE Mar (INR mn)	FY17	FY18	FY19	FY20P	FY21E	FY22E
<b>SOURCES OF FUNDS</b>						
Share Capital	102	102	102	102	102	102
Reserves	2,354	2,869	3,548	5,264	6,779	8,752
<b>Total Shareholders Funds</b>	<b>2,456</b>	<b>2,972</b>	<b>3,650</b>	<b>5,366</b>	<b>6,881</b>	<b>8,854</b>
Long-term Debt	662	1,082	790	479	404	329
Short-term Debt	522	717	852	0	50	100
<b>Total Debt</b>	<b>1,185</b>	<b>1,799</b>	<b>1,642</b>	<b>480</b>	<b>455</b>	<b>430</b>
Minority Interest						
Long-term Provisions & Others	71	117	61	47	61	61
Net Deferred Tax Liability	327	405	507	404	424	445
<b>TOTAL SOURCES OF FUNDS</b>	<b>4,039</b>	<b>5,292</b>	<b>5,859</b>	<b>6,296</b>	<b>7,820</b>	<b>9,790</b>
<b>APPLICATION OF FUNDS</b>						
<b>Net Block</b>	<b>2,201</b>	<b>3,552</b>	<b>3,764</b>	<b>4,235</b>	<b>5,289</b>	<b>5,908</b>
CWIP	348	184	432	449	503	523
Goodwill						
Investments	14	14	14	-	-	-
LT Loans & Advances	254	174	90	139	139	139
Other Non Current Assets	55	62	75	70	73	77
<b>Total Non-current Assets</b>	<b>2,872</b>	<b>3,987</b>	<b>4,376</b>	<b>4,892</b>	<b>6,004</b>	<b>6,646</b>
Inventories	1,114	852	1,057	837	1,272	1,515
Debtors	973	1,238	1,526	1,642	1,814	2,160
Cash & Equivalents	30	32	202	323	1,109	2,296
ST Loans & Advances	2	1	2	2	4	4
Other Current Assets	131	260	322	138	151	166
<b>Total Current Assets</b>	<b>2,250</b>	<b>2,384</b>	<b>3,109</b>	<b>2,941</b>	<b>4,351</b>	<b>6,141</b>
Creditors	809	672	1,240	708	1,492	1,777
Other Current Liabilities	274	406	386	830	1,042	1,220
<b>Total Current Liabilities</b>	<b>1,083</b>	<b>1,078</b>	<b>1,626</b>	<b>1,538</b>	<b>2,535</b>	<b>2,997</b>
<b>Net Current Assets</b>	<b>1,167</b>	<b>1,306</b>	<b>1,484</b>	<b>1,404</b>	<b>1,816</b>	<b>3,144</b>
<b>TOTAL APPLICATION OF FUNDS</b>	<b>4,039</b>	<b>5,292</b>	<b>5,859</b>	<b>6,296</b>	<b>7,820</b>	<b>9,790</b>

Source: Company, HSIE Research

### Consolidated Cash Flow


YE Mar (INR mn)	FY17	FY18	FY19	FY20P	FY21E	FY22E
Reported PBT	739	958	1,302	2,597	2,231	2,852
EO items				(355)		
Interest Expenses	81	81	148	103	58	55
Depreciation	143	157	233	269	311	361
Working Capital Change	(21)	(136)	(9)	201	375	(142)
Tax Paid	(195)	(237)	(363)	(547)	(471)	(606)
<b>OPERATING CASH FLOW ( a )</b>	<b>747</b>	<b>823</b>	<b>1,312</b>	<b>2,267</b>	<b>2,504</b>	<b>2,521</b>
Capex	(659)	(1,344)	(693)	(757)	(1,419)	(1,000)
Free Cash Flow (FCF)	89	(521)	618	1,510	1,085	1,521
Investments	15	-	-	14	-	-
<b>INVESTING CASH FLOW ( b )</b>	<b>(644)</b>	<b>(1,344)</b>	<b>(693)</b>	<b>(742)</b>	<b>(1,419)</b>	<b>(1,000)</b>
Debt Issuance/(Repaid)	85	615	(157)	(1,162)	(25)	(25)
Interest Expenses	(81)	(81)	(148)	(103)	(58)	(55)
FCFE	93	12	314	245	1,002	1,441
Share Capital Issuance	-	-	-	-	-	-
Dividend	(126)	(123)	(201)	(502)	(226)	(251)
Others	4	114	57	363	10	(4)
<b>FINANCING CASH FLOW ( c )</b>	<b>(117)</b>	<b>524</b>	<b>(449)</b>	<b>(1,404)</b>	<b>(299)</b>	<b>(335)</b>
<b>NET CASH FLOW (a+b+c)</b>	<b>(13)</b>	<b>3</b>	<b>169</b>	<b>121</b>	<b>787</b>	<b>1,186</b>
EO Items, Others						
Closing Cash & Equivalents	30	32	202	323	1,109	2,296

### Consolidated Key Ratios

	FY17	FY18	FY19	FY20P	FY21E	FY22E
<b>PROFITABILITY (%)</b>						
GPM	47.4	45.8	45.6	51.2	51.1	49.5
EBITDA Margin	19.0	18.9	19.4	26.1	24.3	25.1
EBIT Margin	16.4	16.9	17.1	24.1	22.5	24.0
APAT Margin	10.1	10.4	9.9	21.7	17.1	18.3
RoE	22.7	23.7	25.3	47.8	28.4	28.3
RoC	15.9	15.9	18.2	32.6	28.2	31.9
RoCE	15.7	15.7	17.7	37.8	25.3	25.8
<b>EFFICIENCY</b>						
Tax Rate (%)	31.9	32.9	35.7	23.2	22.0	22.0
Asset Turnover (x)	1.3	1.2	1.5	1.6	1.3	1.2
Inventory (days)	81	50	46	46	46	46
Debtors (days)	71	73	66	65	65	65
Other Current Assets (days)	10	15	14	5	5	5
Payables (days)	59	40	53	53	53	53
Other Current Liab & Prov (days)	22	32	21	3	6	5
Cash Conversion Cycle (days)	80	68	51	59	57	57
Net Debt/EBITDA (x)	1.2	1.5	0.9	0.1	(0.3)	(0.6)
Net D/E	0.5	0.6	0.4	0.0	(0.1)	(0.2)
Interest Coverage	10.2	12.8	9.8	23.3	39.2	52.6
<b>PER SHARE DATA</b>						
EPS (Rs/sh)	24.7	31.5	41.1	88.2	85.3	109.1
CEPS (Rs/sh)	31.7	39.2	52.5	118.7	100.6	126.8
DPS (Rs/sh)	5.0	7.0	8.0	20.0	9.0	10.0
BV (Rs/sh)	120.3	145.6	178.9	263.1	337.3	434.1
<b>VALUATION</b>						
P/E	18.3	64.7	49.6	23.1	23.9	18.7
P/BV	3.7	14.0	11.4	7.7	6.0	4.7
EV/EBITDA	10.9	37.2	26.2	16.1	16.5	13.0
OCF/EV (%)	5.5	1.9	3.0	6.6	5.9	6.3
FCF/EV (%)	(0.9)	(1.2)	1.4	4.8	2.4	3.8
FCFE/MCAP (%)	(1.0)	0.0	0.5	1.7	2.2	3.4
Dividend Yield (%)	1.1	0.3	0.4	1.0	0.4	0.5

Source: Company, HSIE Research

## RECOMMENDATION HISTORY



Date	CMP	Reco	Target
9-Jul-19	820	BUY	1,309
7-Aug-19	778	BUY	1,369
22-Sep-19	750	BUY	1,380
11-Oct-19	852	BUY	1,380
8-Nov-19	996	BUY	1,770
30-Dec-19	1,069	BUY	1,840
10-Jan-20	1,256	BUY	1,790
6-Feb-20	1,443	BUY	1,840
2-Mar-20	1,511	BUY	2,130
29-Apr-20	1,871	BUY	2,300
26-Jun-20	2,045	BUY	2,500

From 2<sup>nd</sup> March 2020, we have moved to new rating system

## Rating Criteria

BUY: >+15% return potential

ADD: +5% to +15% return potential

REDUCE: -10% to +5% return potential

SELL: >10% Downside return potential

**Disclosure:**

We, Nilesh Ghuge, MMS, Harshad Katkar, MBA & Divya Singhal, CA, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

Research Analyst or his/her relative or HDFC Securities Ltd. **does not have** any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate **does not have** any material conflict of interest.

**Any holding in stock –No**

HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475.

**Disclaimer:**

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: [complianceofficer@hdfcsec.com](mailto:complianceofficer@hdfcsec.com) Phone: (022) 3045 3600

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

**HDFC securities****Institutional Equities**

Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park,

Senapati Bapat Marg, Lower Parel, Mumbai - 400 013

Board: +91-22-6171-7330 [www.hdfcsec.com](http://www.hdfcsec.com)